Mesothelin might have promise as a unique tumour associated antigen for TNBC; it has been screened in 99 primary breast cancers (it was overexpressed in 67% TNBC but < 5% ER(+) or Her2-neu+ type, and was undetectable in non-neoplastic mammary epithelium) [122]. The gene discussed is ERBB2; the disease is breast cancer.